NCT02093585View on ClinicalTrials.gov

Tenofovir Abacavir Platelet Activation Study

PHASE4CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

June 30, 2017

Conditions
HIV
Interventions
DRUG

abacavir (600 mg QD)

DRUG

tenofovir (245 mg QD)

Trial Locations (1)

2100

Rigshospitalet, Klinik for Infektionsmedicin og Reumatologi, 8622, Copenhagen Ø

All Listed Sponsors
lead

Jan Gerstoft

OTHER

NCT02093585 - Tenofovir Abacavir Platelet Activation Study | Biotech Hunter | Biotech Hunter